My ePortfolio Register   

The need to better understand pathways that drive ER+ metastatic breast cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 13.12.16
Views: 2713

Dr Julie Gralow - University of Washington, Washington, USA

While many tumors in patients with ER /HER2- metastatic breast cancer respond to anti-estrogen therapy, almost all will eventually start to grow again despite the estrogen pathway being shut down. Therefore, there is a need to better understand the other pathways involved in tumor cell growth (Pfizer sponsored).

Visit to find out more about the global state of metastatic breast cancer and to learn
about the impact of breast cancer on women, please visit


Breast · Medicines · Biology · Drug development

Related videos

follow us

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence